Unlike in CML, where TP53 mutations are linked to disease progression to blast crisis, in CLL, they are associated with poor response to chemoimmunotherapy, particularly to purine analogs such as fludarabine. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.